Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)]

Autor: Plimack, Elizabeth R., Powles, Thomas, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Waddell, Tom, Alekseev, Boris, Pouliot, Frédéric, Melichar, Bohuslav, Soulières, Denis, Borchiellini, Delphine, McDermott, Raymond S., Vynnychenko, Ihor, Chang, Yen-Hwa, Tamada, Satoshi, Atkins, Michael B., Li, Chenxiang, Perini, Rodolfo, Rhoda Molife, L., Bedke, Jens, Rini, Brian I.
Zdroj: In European Urology November 2023 84(5):e123-e124
Databáze: ScienceDirect
Externí odkaz: